Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novacyt's Total Assets for the quarter that ended in Dec. 2025 was $53.99 Mil.
During the past 12 months, Novacyt's average Total Assets Growth Rate was -50.10% per year.
During the past 3 years, the average Total Assets Growth Rate was -26.90% per year.
During the past 5 years, the average Total Assets Growth Rate was -26.80% per year.
During the past 10 years, the average Total Assets Growth Rate was 10.20% per year.
During the past 13 years, Novacyt's highest 3-Year average Total Assets Growth Rate was 155.30%. The lowest was -26.90%. And the median was 27.20%.
Total Assets is connected with ROA %. Novacyt's annualizedROA % for the quarter that ended in Dec. 2025 was -63.56%. Total Assets is also linked to Revenue through Asset Turnover. Novacyt's Asset Turnover for the quarter that ended in Dec. 2025 was 0.20.
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Novacyt's Asset Turnover for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Novacyt Total Assets Related Terms
Novacyt Total Assets Historical Data
* Premium members only.
The historical data trend for Novacyt's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Novacyt's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novacyt (NVYTF) has a Total Assets of $53.99 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Novacyt and its competitors.
Is Novacyt's Total Assets too high?
Novacyt's current Total Assets is $53.99 Mil. Overall, Novacyt has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Novacyt's Total Assets compare to ABT and SYK?
Novacyt's Total Assets of $53.99 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Medical Devices & Instruments company?
A good Total Assets depends on the Medical Devices & Instruments industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Novacyt and its competitors. Novacyt's current Total Assets is $53.99 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novacyt stock overvalued right now?
Novacyt (NVYTF) has a current Total Assets of $53.99 Mil. The stock's GF Value™ is $0.79, compared to a current price of $0.48 — trading 39.3% below its estimated fair value. The current Total Assets is $53.99 Mil. Novacyt's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Novacyt (NVYTF), the current Total Assets is $53.99 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novacyt (NVYTF) Overvalued in 2026?
Based on GuruFocus' analysis, Novacyt stock appears to be undervalued.
The current stock price of $0.48 is trading 39.3% below its estimated GF Value™ of $0.79.
Key valuation signals for NVYTF:
Total Assets: $53.99 Mil
GF Value™: $0.79 vs. price of $0.48 (39.3% below fair value)
No single metric tells the full story. See the NVYTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. The company operates its business through the following business segments: Primer Design, Yourgene Health and Corporate. Majority of the revenue is generated from Yourgene Health segment. Geographically, the company operates in United Kingdom, France, Europe, America, Asia-Pacific, Middle East and Africa generating majority from Asia- pacific region.
33GF Score
Get the complete analysis for NVYTF
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NVYTF has been successfully added to your 
